Who are IV Tulisokibart's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Imiquimod 3.75% Cream, standard dose of HCQ, Aldara (imiquimod) cream, 5%, Imiquimod and Interferon alpha, Aldara Cream 5%, Imiquimod 5% Topical Cream.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iv-tulisokibart.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

IV Tulisokibart — Competitive Intelligence Brief

IV Tulisokibart (IV Tulisokibart) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TLR7 agonist. Area: Oncology.

phase 3 TLR7 agonist TLR7 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

IV Tulisokibart (IV Tulisokibart) — Merck Sharp & Dohme LLC. Tulisokibart is a TLR7 agonist that activates innate immune responses to enhance anti-tumor immunity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IV Tulisokibart TARGET	IV Tulisokibart	Merck Sharp & Dohme LLC	phase 3	TLR7 agonist	TLR7
Imiquimod 3.75% Cream	Imiquimod 3.75% Cream	Medical University of Graz	marketed	TLR7 agonist	TLR7 (Toll-like receptor 7)
standard dose of HCQ	standard dose of HCQ	University of Sao Paulo General Hospital	marketed	Antimalarial immunosuppressant	Toll-like receptors (TLR7, TLR9); phospholipase C
Aldara (imiquimod) cream, 5%	Aldara (imiquimod) cream, 5%	Graceway Pharmaceuticals, LLC	marketed	TLR7 agonist	TLR7 (Toll-like receptor 7)
Imiquimod and Interferon alpha	Imiquimod and Interferon alpha	The University of Texas Health Science Center, Houston	marketed	Immunostimulant combination	TLR7/8 (imiquimod); Interferon-alpha receptor (interferon alpha)
Aldara Cream 5%	Aldara Cream 5%	Hordinsky, Maria K., MD	marketed	Toll-like receptor 7 (TLR7) agonist	TLR7
Imiquimod 5% Topical Cream	Imiquimod 5% Topical Cream	University of Michigan	marketed	Toll-like receptor 7 (TLR7) agonist	TLR7

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TLR7 agonist class)

Apotex Inc. · 1 drug in this class
Elion Therapeutics, Inc. · 1 drug in this class
Graceway Pharmaceuticals, LLC · 1 drug in this class
MEDA Pharma GmbH & Co. KG · 1 drug in this class
Medical University of Graz · 1 drug in this class
Medical University of Vienna · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IV Tulisokibart — Competitive Intelligence Brief. https://druglandscape.com/ci/iv-tulisokibart. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab